2 Final-Studien (Brust & Leberkrebs) Mkap 35 M$

soll mal wieder über 4$ schliessen  

Premarket sieht super aus
http://www.nasdaq.com/symbol/clsn/premarket  

zum Schluß wirds wieder ein minus !  

mal schauen obs hält !  

Müsste nur mal nachhaltiger sein.  

Sollte noch ein Stück höher gehen in der kommenden Woche!  

 

Celsion Corporation Announces Updated Overall Survival Results from Phase III HEAT Study of ThermoDox® in Primary Liver Cancer14:05 27.01.14


PR Newswire

LAWRENCEVILLE, N.J., Jan. 27, 2014

LAWRENCEVILLE, N.J., Jan. 27, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced that the latest overall survival data from its post-hoc analysis of results from the Company's Phase III HEAT Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radio frequency ablation (RFA), supports the continued clinical development of ThermoDox® in a prospective pivotal Phase III Study, subject to regulatory review and agreement. This analysis followed the announcement on January 31, 2013, that the HEAT Study did not meet its primary endpoint, progression-free survival (PFS).  As provided for in the HEAT Study's Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA), the Company continues to follow patients for overall survival, the secondary endpoint of the Study.  Data from four quarterly reviews of overall survival have been evaluated since the announcement of top line PFS data.

Data from the updated HEAT Study analysis suggests that ThermoDox® may significantly improve overall survival, compared to control, in patients whose lesions undergo RFA treatment for 45 minutes or more.  These findings apply to patients with single HCC lesions (64.4% of the HEAT Study population) from both size cohorts of the HEAT Study (3-5 cm and 5-7 cm) and represent a subgroup of 285 patients (41% of the patients in the HEAT Study).  Updated OS data from this subgroup of patients is summarized below:

•In the patient subgroup treated in the ThermoDox® arm, whose RFA procedure lasted longer than 45 minutes (285 patients or 63% of single lesion patients) clinical results indicate a 55% improvement in overall survival, a Hazard Ratio of 0.64 (95% CI 0.41 – 1.00) and a P-value = 0.0495. Median overall survival for this subgroup has not yet been reached.
•In contrast, the patient subgroup treated with ThermoDox® whose RFA procedure lasted less than 45 minutes in duration (167 patients or 37% of single lesion patients) indicated a Hazard Ratio of 1.12 (95% CI 0.68 – 1.86) and a P-value = 0.66.  Median overall survival for this subgroup has not yet been reached.
•The Hazard Ratios reported above warrants additional clinical development and should be viewed with caution since they are based on a retrospective analysis and the HEAT Study has not reached its median point for overall survival analysis.  Celsion will continue to follow patients in the HEAT Study to the secondary endpoint, overall survival, and will update the subgroup analysis based on RFA heating duration.
"The HEAT Study post-hoc data is compelling.  The combination of ThermoDox® and an optimized RFA treatment appears to have a significant improvement in overall survival in HCC patients," stated Dr. Nicholas Borys, Celsion's Chief Medical Officer.  "While this conclusion is reached based on a post-hoc evaluation, it is nonetheless supported by the consistency of the data seen over a one year follow-up period, and by what is now a statistically significant outcome for overall survival.  Our investigators are convinced that RFA can and should be optimized in future trials."

The HEAT Study and prior post-hoc analyses were presented at three medical conferences in 2013, including the World Conference on Interventional Oncology in May; the European Conference on Interventional Oncology in June and the International Liver Cancer Association Annual Conference in September.  Presentations were made by some of the most highly recognized liver cancer researchers and key HEAT Study investigators.  Quarterly overall survival data analyses have been conducted with the full support of these researchers and clinical investigators.  

Additionally, Celsion has been consulting with its clinical advisors, regulatory and expert statistician consultants and the FDA regarding the study design and statistical plan for its proposed pivotal Phase III clinical trial.  The Company anticipates initiating a multicenter global trial in the first half of 2014.  

"These data continue to support our strong interest in ThermoDox® and its potential as a first line treatment for a significant percentage of the world's 750,000 newly diagnosed HCC patients," noted Michael H. Tardugno, Celsion's President and Chief Executive Officer. "In addition to the FDA, the Company is pursuing regulatory approval of its new Phase III clinical trial in multiple countries, particularly those where HCC's prevalence represents an important health issue.  In parallel with this effort, we are recruiting key CRO partners to initiate the Study rapidly following regulatory agency agreement. With our strong financial resources and the support of the global HCC community, we are confident in our ability to conduct a timely and cash efficient pivotal program."    

About Celsion Corporation

Celsion is dedicated to the development and commercialization of innovative cancer drugs, including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology.  Celsion has research, license or commercialization agreements with leading institutions, including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford.  For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.  Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data, particularly in small subgroups that are not statistically significant; FDA and regulatory uncertainties and risks; the significant expense, time, and risk of failure of conducting clinical trials; HEAT Study data is subject to further verification and review by the HEAT Study Data Management Committee; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses or the possible failure to make such acquisitions or licenses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion's periodic reports and prospectuses filed with the Securities and Exchange Commission.  Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact

Jeffrey W. Church

Senior Vice President and

Chief Financial Officer

609-482-2455

jchurch@celsion.com

SOURCE Celsion Corporation


Quelle: PR Newswire
 

das tönt doch super, wieso sind wir im minus?!
Oder verstehe ich das so falsch?  

Celsion Announces FDA Clearance of the OPTIMA Study - A Pivotal Phase III Trial of ThermoDox in Primary Liver Cancer14:05 24.02.14


PR Newswire

LAWRENCEVILLE, N.J., Feb. 24, 2014

LAWRENCEVILLE, N.J., Feb. 24, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today that the U.S. Food and Drug Administration (FDA) has reviewed and provided clearance for the Company's planned pivotal, double-blind, placebo-controlled Phase III trial of ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radio frequency ablation (RFA) in primary liver cancer, also known as hepatocellular carcinoma (HCC). The trial design is based on a comprehensive analysis of data from the Company's Phase III HEAT Study, which demonstrated that treatment with ThermoDox resulted in a 55% improvement in overall survival in a substantial number of HCC patients that received an optimized RFA treatment.  Celsion expects to launch the study in the first half of 2014.

The Phase III trial, known as the OPTIMA Study, was designed with extensive input from globally recognized HCC researchers and clinicians, and after formal consultation with FDA. The OPTIMA Study is expected to enroll 550 patients globally, with up to 100 sites in the United States, Europe, China and Asia Pacific and will evaluate ThermoDox in combination with RFA, which will be standardized to a minimum of 45 minutes across all investigators and sites for treating lesions 3 to 7 centimeters, versus standardized RFA alone. The primary endpoint for the trial is overall survival (OS).  The statistical plan calls for two interim efficacy analyses by an independent Data Monitoring Committee (iDMC).

"ThermoDox appears to hold great promise as a first-line treatment when used in combination with  optimized RFA, for primary liver cancer, one of the most deadly and prevalent forms of cancer worldwide," stated Nicholas Borys, MD, Celsion's Chief Medical Officer. "Consistency of the retrospective data emerging from the HEAT Study over the past year has been remarkable, and underscores the potential of ThermoDox to extend survival in primary liver cancer patients. Now informed by critical insights from our HEAT Study, I am confident that the OPTIMA Study is robust, well-designed and well-supported by HCC researchers worldwide.  We look forward to initiation and timely completion of this important study."

As reported in January 2014, post-hoc data from the Company's  HEAT Study demonstrate that the patient subgroup in the ThermoDox arm whose RFA procedure lasted longer than 45 minutes (285 patients or 63% of single lesion patients), experienced a 55% improvement in overall survival, with a Hazard Ratio of 0.64 (95% CI 0.41 - 1.00) and a P-value = 0.0495. Median overall survival for this subgroup has not yet been reached. Celsion will continue to follow patients in the HEAT Study on a quarterly basis.

"FDA allowance of the Phase III OPTIMA Study represents a significant step forward in our global development strategy for ThermoDox and establishes a clear regulatory pathway that advances our goal of delivering a new treatment option to patients with this devastating and underserved disease," stated Michael H. Tardugno, Celsion's President and CEO. "In parallel with our efforts in the United States, we continue to advance discussions with regulators in other important global markets, including a recent positive meeting with China FDA (CFDA) and near-term plans to meet with European regulatory authorities."  

In support of the Company's global regulatory efforts, Celsion recently met with CFDA to discuss the Phase III trial, including minimum patient enrollment requirements supporting ThermoDox's registration in China. Based on those discussions, Celsion is submitting an application for accelerated approval of the study in China. Celsion will expand its clinical site footprint in Europe and plans to meet with the European Medicines Agency (EMA) in the first half of 2014.

The HEAT Study and prior post-hoc analyses were presented at three medical conferences in 2013, including the World Conference on Interventional Oncology in May; the European Conference on Interventional Oncology in June and the International Liver Cancer Association Annual Conference in September.  Presentations were made by some of the most highly recognized liver cancer researchers and key HEAT Study investigators.  Quarterly overall survival data analyses have been conducted with the full support of these researchers and clinical investigators.

About Celsion Corporation

Celsion is dedicated to the development and commercialization of innovative cancer drugs, including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology.  Celsion has research, license or commercialization agreements with leading institutions, including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford.  For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.  Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data, particularly in small subgroups; FDA and regulatory uncertainties and risks; the significant expense, time, and risk of failure of conducting clinical trials; HEAT Study data is subject to further verification and review by the HEAT Study Data Management Committee; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses or the possible failure to make such acquisitions or licenses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion's periodic reports and prospectuses filed with the Securities and Exchange Commission.  Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Celsion Investor Contact

Jeffrey W. Church

Sr. Vice President and CFO

609-482-2455

jchurch@celsion.com

SOURCE Celsion Corporation


Quelle: PR Newswire
 

geht Afterhour gut was ab !!  

http://www.nasdaq.com/symbol/clsn/after-hours  

http://www.nasdaq.com/symbol/clsn/real-time  

Keep it up  

But I have a Question  

Can I ask?  

10 Mio. $ Offering

• bis zu 5 Mio. Aktien zu je 2$
  

https://investors.imunon.com/news-releases/news-release-details/imunon-announces-10-million-registered-direct-offering-priced

Der Schlusskurs lag gestern bei 3,32$

 

Zahlen für Q2/24

• keine Umsätze
  
• Verlust 4,8 Mio. $
  
• Cash 5,3 Mio. $
  
• MK 14 Mio. $
  

https://investors.imunon.com/news-releases/...4-financial-results-and

Selbst mit den 10 Mio. $ aus dem letzten Offering ist das Grundproblem hier die überschaubare Cashreichweite (von ca. 3 Quartalen)

 

Zahlen für Q3/24

• keine Umsätze
  
• Verlust 4,8 Mio. $
• Cash 10 Mio. $
  
• MK 11,5 Mio. $
  

fund its operations into the third quarter of 2025

https://investors.imunon.com/news-releases/...al-results-and-provides

 

Analystenschätzungen
Verkaufen - Analystenschätzungen - Kaufen
Durchschnittl.  Empfehlung  KAUFEN
Anzahl Analysten   4
Letzter Schlusskurs       0,8672USD
Mittleres Kursziel         13,20USD
Abstand / Mittleres Kursziel      +1.422,14 %
Höchstes Kursziel          29,00USD
Abstand / Höchstes Kursziel      +3.244,10 %
Niedrigstes Kursziel        5,000USD
Abstand / Niedrigstes Kursziel     +476,57 %

https://de.marketscreener.com/kurs/aktie/...170/analystenerwartungen/

Ich bin gestern auf dem Wert aufmerksam geworden.
Betrachte es für mich auf 2025 Dezember. Also Langzeit Invest.

Habe versucht heute noch günstiger rein zu kommen seit 8:00 Uhr. Keine Chance. Der Spread vergrößert sich nur.
Bin für 0,836 € drin inklusive Kosten.

Mein Ziel seit der gestrigen Beobachtung zu kaufen bevor die Ammis wieder um 16:00 Uhr starten.


 

Sind hier nicht aussagekräftig. Zum einen meist veraltet, zum anderen sind Analysten dafür bekannt ihre Kursziele „nachzuziehen“  

Anstehende Termine für Imunon, Inc.
27.03.2025§ Q4 2024 Ergebnisveröffentlichung (geplant)
19.05.2025§ Q1 2025 Ergebnisveröffentlichung (geplant)
13.08.2025§ Q2 2025 Ergebnisveröffentlichung (geplant)
17.11.2025§ Q3 2025 Ergebnisveröffentlichung (geplant)

Ich halte "MarketScreener" immer noch für eine gute Quelle um generell an Informationen zu kommen.

Mit Runen würfeln hat an der  Börse noch nie was gebracht. Oder ?  

Die Ammis setzen anscheinend auch auf die Aktie wie ich am Freitag beobachten konnte.
Der Wert hat sich auch in den Staaten heute Vorbörslich ganz gut gehalten.
Ich bin hier mit Risiko Kapital drin, langfristig darauf angelegt eine hohe Rendite ein zu fahren.

Ein zweites Langzeit Invest mit Risiko Kapital von mir hat sich auch ganz gut erholt.
Die Ammis sind daran auch anscheinend gut interessiert, wie ich am Freitag beobachten konnte.
Mit den Canada Werten ist es ja immer so eine Sache.
Mir ist es gelungen am Freitag über die Canada Börse an mehr Infos ran zu kommen.

Eat & Beyond Global Aktie       WKN A3D73Z - ISIN  CA27785T2092 - Ticker  EATS  988

Mit diesen beiden Werten bin ich mit je Summe "X" auf Risiko gegangen. Langfristig investiert mit der Aussicht auf mehrere 100%.
Diese Aussagen sind nur meine rein persönliche Meinung und ist weder eine Kauf noch Verkauf Empfehlung.

So ich muss jetzt Schluss machen, weil ich mit Faktor 12 Zertifikat in den Staaten unterwegs bin seit Kauf um 14:48 Uhr

Frohe Feiertage den hier investierten im Voraus.  

Keine Ahnung irgentwas mit Sonderzeichen. Altbekanntes Problem ohne eine erkennbare Lösung.